Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?
Open accessThe DOI matches its Crossref record; 265 of the 267 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Chronic inflammatory skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa are systemic conditions marked by persistent immune activation. Growing evidence links them to molecular and vascular ageing, including oxidative stress, endothelial dysfunction, and reduced expression of longevity-related proteins like Klotho and SIRT1. This narrative review examines how Th17- and Th2-driven inflammation contributes to systemic inflammageing. Key cytokines—IL-17, IL-23, IL-4, IL-13, and IL-31—promote endothelial damage, oxidative stress, and metabolic dysfunction. We highlight the role of vascular biomarkers (e.g., VCAM-1, ICAM-1, ST2, P-selectin) and immune cell senescence as indicators of ageing. Finally, we explore whether biologic therapies targeting these pathways may attenuate inflammation-driven ageing. Chronic skin diseases may thus serve as accessible models of systemic inflammageing and targets for early intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These features are not only diagnostically useful but also reflect disease-specific immune mechanisms that increasingly inform therapeutic targeting across inflammatory dermatoses [1,2,3,4,5].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“T lymphocytes play a central role in coordinating disease-specific immune responses, with distinct subtypes such as T helper 1 (Th1), T helper 2 (Th2), and T helper 17 (Th17) driving various inflammatory phenotypes.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The cutaneous immune microenvironment is predominantly driven by type 2 immune responses (mediated by Th2) with additional involvement of Th22 and Th1 pathways in chronic stages.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to circulating immune cells, tissue-resident memory T cells contribute to the persistence and recurrence of inflammation, emphasizing the importance of local immune regulation.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In atopic dermatitis, the most characteristic features are spongiosis, epidermal barrier disruption, and a superficial perivascular lymphocytic infiltrate.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 1×
“It is produced by dendritic cells (DCs), monocytes, and macrophages, which act as antigen-presenting cells (APCs) in activated skin and mucous membranes [62,67].”
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690 · cited 5×
“This is a self-sustaining mechanism that causing the persistence of inflammation (Figure 2) [29,30].”
InfluentialOxidative stress and autophagy: The clash between damage and metabolic needs
Filomeni, G., De Zio, D., & Cecconi, F. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.150 · Cited by 2,195 · cited 2×
“Moreover, they can disrupt signalling pathways, cause mitochondrial dysfunction, and contribute to inflammation and senescence [3,18,19].”
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 1×
“It has demonstrated beneficial effects in alleviating pruritus, pain, and scaling [135,137–139].”
Suppression of Aging in Mice by the Hormone Klotho
Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., McGuinness, O. P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., et al. (2005) · Science · doi:10.1126/science.1112766 · Cited by 1,935 · cited 1×
“The expression of this protein decreases with age and is further reduced in conditions such as kidney failure, diabetes, and neurodegenerative diseases like Alzheimer’s [26–28].”
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908 · cited 2×
“These mechanisms are fundamental to the pathogenesis of the disease, contributing to the maintenance of chronic inflammation and the exacerbation of symptoms [85,86].”
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874 · cited 2×
“It was approved by the U.S. Food and Drug Administration (FDA) in 2009 for the treatment of moderate to severe psoriasis [135,160–162].”
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585 · cited 1×
“In response to stimulation by IL-23 and IL-1 β , activated Th17 lymphocytes produce several proinflammatory cytokines, including IL-17A, IL-17F, IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IFN-γ [31,65,66,70–73].”
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261 · cited 3×
“Dupilumab, a monoclonal antibody targeting the interleukin-4 receptor α (IL-4R α ), blocks the signalling of both IL-4 and IL-13, key mediators of the Th2 inflammatory axis involved not only in atopic dermatitis but also in the development of other allergic diseases such as asthma [38].”
Proinflammatory Cytokines, Aging, and Age-Related Diseases
Michaud, M., Balardy, L., Moulis, G., Gaudin, C., Peyrot, C., Vellas, B., Cesari, M., & Nourhashemi, F. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.009 · Cited by 1,094 · cited 1×
“Serum IL-6 levels can be used as indicators of disease activity and severity, and a decrease following biological therapy enables the assessment of treatment response in patients with psoriasis [218,221,222].”
McGeachy, M. J., Chen, Y., Tato, C. M., Laurence, A., Joyce-Shaikh, B., Blumenschein, W. M., McClanahan, T. K., O'Shea, J. J., & Cua, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1698 · Cited by 1,074 · cited 2×
“Together, TGF-β and IL-6 also induce the expression of the primary Th17-specific transcription factor, retinoid-related orphan receptor-γ t (ROR-γ t) [65,66].”
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S. R., Haugen, H. S., Maurer, M., Harder, B., Johnston, J., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,015 · cited 1×
“It belongs to the IL-6 cytokine family, and its receptor is a heterodimeric complex composed of the IL-31RA subunit and the oncostatin M receptor (OSMR) [83,91–93].”
IL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005 · cited 1×
“The IL-31RA receptor is highly expressed in the dorsal root ganglia (DRGs), where the cell bodies of cutaneous sensory neurons are located [92,97].”
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“Its systemic effects extend beyond the immune system, negatively impacting various organs and physiological functions— including the skin, cardiovascular system, and central nervous system—thereby increasing the overall burden of age-related morbidity [59–61].”
Immunosenescence: molecular mechanisms and diseases
Liu, Z., Liang, Q., Ren, Y., Guo, C., Ge, X., Wang, L., Cheng, Q., Luo, P., Zhang, Y., & Han, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01451-2 · Cited by 960 · cited 3×
“Key systemic features of immunosenescence include thymic involution and hematopoietic stem cell (HSC) dysfunction [1,3,8,9].”
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889 · cited 1×
“They are effective and well tolerated, providing symptom relief, improved skin condition, and enhanced quality of life in patients with psoriasis [39,135,187–189].”
Mechanisms regulating skin immunity and inflammation
Pasparakis, M., Haase, I., & Nestle, F. O. (2014) · Nature Reviews Immunology · doi:10.1038/nri3646 · Cited by 886 · cited 1×
“Its systemic effects extend beyond the immune system, negatively impacting various organs and physiological functions— including the skin, cardiovascular system, and central nervous system—thereby increasing the overall burden of age-related morbidity [59–61].”
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Cevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G., Buhl, T., Ikoma, A., Buddenkotte, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.048 · Cited by 804 · cited 1×
“The IL-31RA/OSMR complex on IL-31RA+/TRPV1+/TRPA1+ neurons constitutes a key neuroimmune component in the generation of Th2-dependent itch in chronic inflammatory skin diseases [37].”
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766 · cited 1×
“This disease is characterised by a predominant immune response driven by activation of the Th2 inflammatory axis, making blockade of the key cytokines in this pathway an effective therapeutic approach [7,112,113].”
Reich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y.-K., & Gordon, K. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.042 · Cited by 761
Aging and vascular endothelial function in humans
Seals, D. R., Jablonski, K. L., & Donato, A. J. (2011) · Clinical Science · doi:10.1042/cs20100476 · Cited by 725 · cited 1×
“These substances are involved in vasodilation and exhibit thrombolytic and vasoprotective effects [78].”
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Regulation of SIRT1 and Its Roles in Inflammation
Yang, Y., Liu, Y., Wang, Y., Chao, Y., Zhang, J., Jia, Y., Tie, J., & Hu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.831168 · Cited by 690 · cited 2×
“This enables SIRT1 to significantly contribute to the regulation of processes responsible for antioxidation, DNA damage repair, mitochondrial function, and autophagy [22,23,25].”
Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes
Junttila, I. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00888 · Cited by 684 · cited 1×
“The receptor type depends on the cell and determines the nature of the immune response [89,90].”
SIRT1 and aging related signaling pathways
Chen, C., Zhou, M., Ge, Y., & Wang, X. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111215 · Cited by 683 · cited 8×
“SIRT1 modulates FoxO proteins through deacetylation, enhancing their ability to induce cell cycle arrest and confer resistance to oxidative stress [23,25].”
InfluentialGordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31713-6 · Cited by 678 · cited 2×
“Its high efficacy in the treatment of moderate to severe psoriasis has been confirmed in clinical trials [135,165,174–176].”
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668 · cited 1×
“Other drugs targeting IL-6 include sirukumab, olokizumab, and clazakizumab [223].”
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668 · cited 1×
“However, this phenomenon remains a subject of ongoing clinical research [135,156–159].”
Th2 Cytokines and Atopic Dermatitis
B. Brandt, E. (2011) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000110 · Cited by 655 · cited 3×
“Nevertheless, current evidence indicates that elevated IgE levels are not essential for the development of atopic dermatitis [83].”
Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638 · cited 2×
“It binds specifically to IL-13 with high affinity, thus preventing receptor interaction and downstream signalling [124].”
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569 · cited 1×
“It is approved for the treatment of moderate to severe plaque psoriasis and has demonstrated good efficacy in this indication [180,181].”
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551 · cited 1×
“Compared to other biologics, such as ustekinumab and etanercept, secukinumab, with a comparable safety profile, provides better reduction in disease symptoms and greater improvement in quality of life [141].”
Le Floc’h, A., Allinne, J., Nagashima, K., Scott, G., Birchard, D., Asrat, S., Bai, Y., Lim, W. K., Martin, J., Huang, T., et al. (2020) · Allergy · doi:10.1111/all.14151 · Cited by 545 · cited 1×
“…IL-23, and TNF-α , can effectively reduce inflammation and limit excessive immune system activation, potentially counteracting inflammageing [63,205–209] A study by Florian TL et al. analysed the relationship between levels of TNF-α , IL-23, IL-17A, and IL-17F and the duration and severity of…”
Management of psoriasis as a systemic disease: what is the evidence?
Korman, N. J. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18245 · Cited by 539 · cited 1×
“…the skin, often coexists with cardiovascular diseases, atherosclerosis, metabolic syndrome, type 2 diabetes, obesity, psoriatic arthritis (PsA), inflammatory bowel disease, and non-alcoholic fatty liver disease (NAFLD), all of which occur more frequently than in the general population [210–212].”
Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments
Zuo, L., Prather, E. R., Stetskiv, M., Garrison, D. E., Meade, J. R., Peace, T. I., & Zhou, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184472 · Cited by 539 · cited 1×
“Excess ROS promotes inflammageing, accelerating the development of diseases associated with biological ageing [196].”
Mitochondrial dysfunction and the inflammatory response
López-Armada, M. J., Riveiro-Naveira, R. R., Vaamonde-García, C., & Valcárcel-Ares, M. N. (2013) · Mitochondrion · doi:10.1016/j.mito.2013.01.003 · Cited by 530
Simpson, E. L., Paller, A. S., Siegfried, E. C., Boguniewicz, M., Sher, L., Gooderham, M. J., Beck, L. A., Guttman-Yassky, E., Pariser, D., Blauvelt, A., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3336 · Cited by 524 · cited 1×
“It is used in patients with moderate to severe atopic dermatitis and has a favourable safety profile, confirmed by numerous clinical trials [38,115–122].”
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Papp, K. A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J. G., Lacour, J.-P., Menter, A., Philipp, S., Sofen, H., Tyring, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607017 · Cited by 514
Biological Versus Chronological Aging
Hamczyk, M. R., Nevado, R. M., Barettino, A., Fuster, V., & Andrés, V. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.062 · Cited by 489 · cited 4×
“Chronic skin diseases contribute to inflammageing by sustaining immune cell activation and altering ageing-related biomarkers [40,64,77,216].”
Influentialde Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479 · cited 1×
“This combination is often used to increase treatment efficacy and achieve better disease control [38,123].”
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Brembilla, N. C., Senra, L., & Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01682 · Cited by 475
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475 · cited 5×
“However, in prolonged inflammatory states, sVCAM and sICAM are released into the plasma, contributing to endothelial damage and vascular dysfunction [42,43].”
InfluentialHamilton, J. D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 469 · cited 1×
“These molecular changes correlated with clinical improvement [121].”
Inflammation, Aging, and Cardiovascular Disease
Liberale, L., Badimon, L., Montecucco, F., Lüscher, T. F., Libby, P., & Camici, G. G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.017 · Cited by 462 · cited 2×
“Importantly, it reflects a shift in the immune system towards a proinflammatory phenotype, even in the absence of acute infection, and often coexists with immunosenescence, further compromising immune competence [1,2,29,30].”
Kimura, M., Stone, R. C., Hunt, S. C., Skurnick, J., Lu, X., Cao, X., Harley, C. B., & Aviv, A. (2010) · Nature Protocols · doi:10.1038/nprot.2010.124 · Cited by 459 · cited 1×
“This method is applied in epidemiological studies evaluating leukocyte telomere length but can also be used to measure telomeres in other cell types [57].”
Endothelial cell senescence in aging-related vascular dysfunction
Jia, G., Aroor, A. R., Jia, C., & Sowers, J. R. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.008 · Cited by 454 · cited 10×
“Klotho deficiency leads to endothelial dysfunction, arterial stiffness, hypertension, and impaired angiogenesis, while high plasma levels reduce the risk of cardiovascular diseases, including stroke [18,52].”
InfluentialSkin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis
Yang, G., Seok, J. K., Kang, H. C., Cho, Y.-Y., Lee, H. S., & Lee, J. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082867 · Cited by 442 · cited 1×
“This contributes to the exacerbation of persistent skin inflammation driven by Th2 lymphocyte activity [105,106].”
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Aging of hematopoietic stem cells
de Haan, G., & Lazare, S. S. (2018) · Blood · doi:10.1182/blood-2017-06-746412 · Cited by 432
ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders
Singh, V., Kaur, R., Kumari, P., Pasricha, C., & Singh, R. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117487 · Cited by 432 · cited 4×
“Additionally, they may function as diagnostic markers for assessing cardiovascular risk in patients with chronic inflammatory diseases [43,226,227] With age and biological ageing, serum levels of VCAM-1 and ICAM-1 increase, a change associated with the process of inflammageing [220].”
InfluentialBimekizumab versus Secukinumab in Plaque Psoriasis
Reich, K., Warren, R. B., Lebwohl, M., Gooderham, M., Strober, B., Langley, R. G., Paul, C., De Cuyper, D., Vanvoorden, V., Madden, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102383 · Cited by 424 · cited 1×
“However, bimekizumab was associated with a higher incidence of oral candidiasis, which was typically mild to moderate in severity [153–155].”
Furue, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155382 · Cited by 419 · cited 3×
“Loss-of-function mutations in the FLG gene, which encodes filaggrin, are among the main risk factors for developing atopic dermatitis [89,106].”
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Yusuf‐Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S., & Siahaan, T. J. (2002) · Medicinal Research Reviews · doi:10.1002/med.10001 · Cited by 408 · cited 1×
“Their expression may be elevated in chronic inflammatory skin diseases, such as psoriasis [43,225].”
Nash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G.-R., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31429-0 · Cited by 405
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., & Fang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594735 · Cited by 386 · cited 2×
“Interleukin-23, acting through the IL-23R receptor—whose expression is upregulated upon activation of Th17 lymphocytes—initiates a signalling pathway involving the transcription factor STAT3 and stabilises the expression of the transcription factor ROR-γ t [63].”
Validation of biomarkers of aging
Moqri, M., Herzog, C., Poganik, J. R., Ying, K., Justice, J. N., Belsky, D. W., Higgins-Chen, A. T., Chen, B. H., Cohen, A. A., Fuellen, G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02784-9 · Cited by 361 · cited 1×
“Biomarkers of ageing aim to predict biological age—reflecting the cumulative burden of molecular damage [41]—and often include indicators of chronic, low-grade inflammation, which plays a central role in vascular decline [40].”
The concept of psoriasis as a systemic inflammation: implications for disease management
Reich, K. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04410.x · Cited by 360
Inflammaging decreases adaptive and innate immune responses in mice and humans
Frasca, D., & Blomberg, B. B. (2016) · Biogerontology · doi:10.1007/s10522-015-9578-8 · Cited by 357
Mease, P. J., Rahman, P., Gottlieb, A. B., Kollmeier, A. P., Hsia, E. C., Xu, X. L., Sheng, S., Agarwal, P., Zhou, B., Zhuang, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30263-4 · Cited by 355
Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Mollanazar, N. K., Smith, P. K., & Yosipovitch, G. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8488-5 · Cited by 353 · cited 1×
“IL-31, as a pruritogenic cytokine, can directly stimulate primary sensory neurons to induce itch and also modulate their sensitivity to other itch mediators such as cytokines IL-4, IL-13, TSLP, and substance P [94,99].”
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Guttman-Yassky, E., Thaçi, D., Irvine, A. D., Stein Gold, L., Blauvelt, A., Simpson, E. L., Chu, C.-Y., Liu, Z., Gontijo Lima, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206714 · Cited by 345 · cited 1×
“This drug prevents the formation of the IL-4R α /IL-13R α 1 heterodimer receptor signalling complex, effectively blocking the IL-13-dependent signalling pathway and reducing the associated inflammatory process [130].”
Kimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00022-3 · Cited by 343 · cited 1×
“The results demonstrated rapid clinical improvement and a sustained therapeutic response [143].”
Simpson, E. L., Flohr, C., Eichenfield, L. F., Bieber, T., Sofen, H., Taïeb, A., Owen, R., Putnam, W., Castro, M., DeBusk, K., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.017 · Cited by 331 · cited 1×
“Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity and did not require treatment discontinuation [129,131,132].”
Silverberg, J. I., Toth, D., Bieber, T., Alexis, A. F., Elewski, B. E., Pink, A. E., Hijnen, D., Jensen, T. N., Bang, B., Olsen, C. K., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19573 · Cited by 326 · cited 2×
“The efficacy and safety of tralokinumab have been confirmed in Phase II and III clinical trials [124–127].”
Skin Aging, Cellular Senescence and Natural Polyphenols
Csekes, E., & Račková, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312641 · Cited by 320
Biomarkers of Aging: From Function to Molecular Biology
Wagner, K.-H., Cameron-Smith, D., Wessner, B., & Franzke, B. (2016) · Nutrients · doi:10.3390/nu8060338 · Cited by 304
Reich, K., Gooderham, M., Thaçi, D., Crowley, J. J., Ryan, C., Krueger, J. G., Tsai, T.-F., Flack, M., Gu, Y., Williams, D. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30952-3 · Cited by 301
Interconnections between Inflammageing and Immunosenescence during Ageing
Teissier, T., Boulanger, E., & Cox, L. S. (2022) · Cells · doi:10.3390/cells11030359 · Cited by 301
Bogeska, R., Mikecin, A.-M., Kaschutnig, P., Fawaz, M., Büchler-Schäff, M., Le, D., Ganuza, M., Vollmer, A., Paffenholz, S. V., Asada, N., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.06.012 · Cited by 299 · cited 1×
“Prolonged exposure to chronic inflammation exacerbates HSC senescence, further impairing their function [12,13].”
The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves
Feld, M., Garcia, R., Buddenkotte, J., Katayama, S., Lewis, K., Muirhead, G., Hevezi, P., Plesser, K., Schrumpf, H., Krjutskov, K., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.02.020 · Cited by 286 · cited 1×
“IL-31, as a neuroimmune modulator, also induces a distinct transcriptional programme in sensory neurons that leads to nerve fibre proliferation, which may explain why patients with atopic dermatitis exhibit increased sensitivity to minimal stimuli that provoke persistent itch [100].”
Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels
Barbalic, M., Dupuis, J., Dehghan, A., Bis, J. C., Hoogeveen, R. C., Schnabel, R. B., Nambi, V., Bretler, M., Smith, N. L., Peters, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq061 · Cited by 279 · cited 1×
“The ELISA method is also used to measure soluble P-selectin [55] and hsCRP. HsCRP can be measured in both fresh and frozen plasma and is one of the most frequently analysed biomarkers in the context of cardiovascular disease risk assessment [56].”
Karbach, S., Croxford, A. L., Oelze, M., Schüler, R., Minwegen, D., Wegner, J., Koukes, L., Yogev, N., Nikolaev, A., Reißig, S., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304108 · Cited by 261 · cited 2×
“This persistent inflammatory state contributes to endothelial dysfunction, oxidative stress, immunosenescence, and altered expression of ageing-related genes and proteins, collectively reflecting inflammageing [81,192–200].”
Brunner, P. M., Suárez-Fariñas, M., He, H., Malik, K., Wen, H.-C., Gonzalez, J., Chan, T. C.-C., Estrada, Y., Zheng, X., Khattri, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09207-z · Cited by 260 · cited 4×
“The systemic nature of atopic dermatitis also leads to an increased risk of cardiovascular complications [81,213].”
InfluentialDeleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.074 · Cited by 255
Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis
Dowlatshahi, E. A., van der Voort, E. A. M., Arends, L. R., & Nijsten, T. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12355 · Cited by 251 · cited 2×
“This persistent inflammatory state contributes to endothelial dysfunction, oxidative stress, immunosenescence, and altered expression of ageing-related genes and proteins, collectively reflecting inflammageing [81,192–200].”
Klotho, Aging, and the Failing Kidney
Buchanan, S., Combet, E., Stenvinkel, P., & Shiels, P. G. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00560 · Cited by 239 · cited 1×
“Klotho deficiency leads to endothelial dysfunction, arterial stiffness, hypertension, and impaired angiogenesis, while high plasma levels reduce the risk of cardiovascular diseases, including stroke [18,52].”
The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
Facheris, P., Jeffery, J., Del Duca, E., & Guttman-Yassky, E. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00992-4 · Cited by 237
von Stebut, E., Reich, K., Thaçi, D., Koenig, W., Pinter, A., Körber, A., Rassaf, T., Waisman, A., Mani, V., Yates, D., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.042 · Cited by 224 · cited 2×
“Biological therapy targeting IL-17A, which contributes to accelerated endothelial cell ageing, improves vascular function and helps prevent ageing-related complications [79,201,203].”
Pilkington, S. M., Bulfone-Paus, S., Griffiths, C. E. M., & Watson, R. E. B. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.006 · Cited by 219 · cited 3×
“Chronic skin diseases contribute to inflammageing by sustaining immune cell activation and altering ageing-related biomarkers [40,64,77,216].”
Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations
Prud’homme, G. J., Kurt, M., & Wang, Q. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.931331 · Cited by 219 · cited 6×
“Membrane-bound and soluble forms of Klotho serve as coreceptors for FGF23, forming a complex with FGFR1c that reduces renal phosphate reabsorption and suppresses 1 α -hydroxylase activity, thereby decreasing intestinal phosphate and calcium absorption through reduced vitamin D activation [26,29].”
InfluentialAge‐related thymic involution: Mechanisms and functional impact
Liang, Z., Dong, X., Zhang, Z., Zhang, Q., & Zhao, Y. (2022) · Aging Cell · doi:10.1111/acel.13671 · Cited by 218 · cited 1×
“Thymic regeneration could offer a promising approach to counteract immunosenescence [8–10].”
Blauvelt, A., Leonardi, C. L., Gooderham, M., Papp, K. A., Philipp, S., Wu, J. J., Igarashi, A., Flack, M., Geng, Z., Wu, T., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0723 · Cited by 217 · cited 1×
“This drug can be safely used in long-term psoriasis therapy, is well tolerated and demonstrates a more favourable clinical effect in terms of skin clearance from psoriatic lesions compared to ustekinumab and adalimumab [174–179].”
Oxidative Stress and Atopic Dermatitis
Bertino, L., Guarneri, F., Cannavò, S. P., Casciaro, M., Pioggia, G., & Gangemi, S. (2020) · Antioxidants · doi:10.3390/antiox9030196 · Cited by 210 · cited 1×
“These phenomena are observed both in the skin and systemically, in the plasma and blood, emphasising the systemic nature of these disorders [234–237].”
Immunosenescence and inflammaging: Mechanisms and role in diseases
Ajoolabady, A., Praticò, D., Tang, D., Zhou, S., Franceschi, C., & Ren, J. T. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102540 · Cited by 197 · cited 4×
“Importantly, it reflects a shift in the immune system towards a proinflammatory phenotype, even in the absence of acute infection, and often coexists with immunosenescence, further compromising immune competence [1,2,29,30].”
InfluentialIL-4 Regulates Skin Homeostasis and the Predisposition toward Allergic Skin Inflammation
Sehra, S., Yao, Y., Howell, M. D., Nguyen, E. T., Kansas, G. S., Leung, D. Y. M., Travers, J. B., & Kaplan, M. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901860 · Cited by 195 · cited 2×
“IL-4 also inhibits the expression of genes involved in innate immunity, including those within the EDC [87,106].”
Schmitt, J., Zhang, Z., Wozel, G., Meurer, M., & Kirch, W. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08732.x · Cited by 195 · cited 1×
“Among TNF-α inhibitors, infliximab is the most effective drug for treating psoriasis, followed by adalimumab, while etanercept exhibits the weakest therapeutic effect in this indication [187,190].”
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192 · cited 1×
“…IL-23, and TNF-α , can effectively reduce inflammation and limit excessive immune system activation, potentially counteracting inflammageing [63,205–209] A study by Florian TL et al. analysed the relationship between levels of TNF-α , IL-23, IL-17A, and IL-17F and the duration and severity of…”
Neuroimmune communication regulating pruritus in atopic dermatitis
Steinhoff, M., Ahmad, F., Pandey, A., Datsi, A., AlHammadi, A., Al-Khawaga, S., Al-Malki, A., Meng, J., Alam, M., & Buddenkotte, J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.010 · Cited by 190 · cited 1×
“The IL-31/IL-31RA immune axis may also contribute to inflammatory processes and skin barrier dysfunction, although the precise mechanisms underlying its action remain unclear [101].”
Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E. M., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.037 · Cited by 189 · cited 1×
“Simultaneous blockade of both cytokines, which are key mediators of the Th17-dependent inflammatory axis, may lead to more effective suppression of inflammation than neutralising IL-17A alone in patients with moderate to severe psoriasis [152–154].”
Krueger, J. G., Wharton, K. A., Schlitt, T., Suprun, M., Torene, R. I., Jiang, X., Wang, C. Q., Fuentes-Duculan, J., Hartmann, N., Peters, T., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.04.029 · Cited by 188 · cited 2×
“It has demonstrated beneficial effects in alleviating pruritus, pain, and scaling [135,137–139].”
Immunosenescence: signaling pathways, diseases and therapeutic targets
Fu, Y., Wang, B., Alu, A., Hong, W., Hong, L., He, X., Shi, H., Cheng, P., & Yang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02371-z · Cited by 187
Yang, K., Oak, A. S. W., & Elewski, B. E. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00578-0 · Cited by 185 · cited 2×
“However, this phenomenon remains a subject of ongoing clinical research [135,156–159].”
Chong, W. P., Mattapallil, M. J., Raychaudhuri, K., Bing, S. J., Wu, S., Zhong, Y., Wang, W., Chen, Z., Silver, P. B., Jittayasothorn, Y., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.022 · Cited by 184 · cited 1×
“IL-17 is a key mediator of sustained chronic inflammation, especially in immune-mediated diseases such as psoriasis (Figure 3) [32,69,74,75].”
Singh, A., Schurman, S. H., Bektas, A., Kaileh, M., Roy, R., Wilson, D. M., Sen, R., & Ferrucci, L. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041197 · Cited by 182 · cited 1×
“Chronic skin diseases contribute to inflammageing by sustaining immune cell activation and altering ageing-related biomarkers [40,64,77,216].”
Comorbidities of atopic dermatitis—what does the evidence say?
Thyssen, J. P., Halling, A.-S., Schmid-Grendelmeier, P., Guttman-Yassky, E., & Silverberg, J. I. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.12.002 · Cited by 179
Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K. B., Ferris, L. K., Langley, R. G., Tada, Y., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18851 · Cited by 175 · cited 1×
“Another key advantage is its faster onset of therapeutic effect compared to IL-23 inhibitors [147,150,151].”
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
Krueger, J. G., Eyerich, K., Kuchroo, V. K., Ritchlin, C. T., Abreu, M. T., Elloso, M. M., Fourie, A. M., Fakharzadeh, S. S., Sherlock, J. P., Yang, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1331217 · Cited by 175 · cited 1×
“In response to stimulation by IL-23 and IL-1 β , activated Th17 lymphocytes produce several proinflammatory cytokines, including IL-17A, IL-17F, IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IFN-γ [31,65,66,70–73].”
Neuroimmune interactions in chronic itch of atopic dermatitis
Yosipovitch, G., Berger, T., & Fassett, M. S. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15973 · Cited by 173 · cited 2×
“This complex is expressed on TRPV1+/TRPA1+ sensory neurons in the dorsal root ganglia, as well as on keratinocytes and skin immune cells, including T lymphocytes [94,95].”
Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs
Kudlova, N., De Sanctis, J. B., & Hajduch, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084168 · Cited by 171
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Doney, L., Dressler, C., Hua, C., Hughes, C., Naldi, L., Afach, S., & Le Cleach, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub4 · Cited by 170 · cited 8×
“They are effective and well tolerated, providing symptom relief, improved skin condition, and enhanced quality of life in patients with psoriasis [39,135,187–189].”
InfluentialSilverwood, R. J., Forbes, H. J., Abuabara, K., Ascott, A., Schmidt, M., Schmidt, S. A. J., Smeeth, L., & Langan, S. M. (2018) · BMJ · doi:10.1136/bmj.k1786 · Cited by 168 · cited 3×
“…and vascular damage, and is associated with elevated levels of inflammatory biomarkers, thereby facilitating the development of comorbidities [7,60,108] Studies have shown that chronic activation of the Th2 axis in adult patients with atopic dermatitis is associated with an increased risk of…”
Pruritus as a Distinctive Feature of Type 2 Inflammation
Garcovich, S., Maurelli, M., Gisondi, P., Peris, K., Yosipovitch, G., & Girolomoni, G. (2021) · Vaccines · doi:10.3390/vaccines9030303 · Cited by 168 · cited 2×
“This complex is expressed on TRPV1+/TRPA1+ sensory neurons in the dorsal root ganglia, as well as on keratinocytes and skin immune cells, including T lymphocytes [94,95].”
The Involvement of Oxidative Stress in Psoriasis: A Systematic Review
Dobrică, E.-C., Cozma, M.-A., Găman, M., Voiculescu, V.-M., & Găman, A. M. (2022) · Antioxidants · doi:10.3390/antiox11020282 · Cited by 168 · cited 2×
“These phenomena are observed both in the skin and systemically, in the plasma and blood, emphasising the systemic nature of these disorders [234–237].”
Chu, A. W. L., Wong, M. M., Rayner, D. G., Guyatt, G. H., Díaz Martinez, J. P., Ceccacci, R., Zhao, I. X., McMullen, E., Srivastava, A., Wang, J., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.029 · Cited by 168 · cited 1×
“They demonstrate moderate effectiveness and have a favourable safety profile [114].”
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis
Paller, A. S., Flohr, C., Cork, M. J., Bewley, A., Blauvelt, A., Hong, H., Imafuku, S., Schuttelaar, M. L. A., Simpson, E. L., Soong, W., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.0627 · Cited by 164
Blauvelt, A., Thyssen, J. P., Guttman-Yassky, E., Bieber, T., Serra-Baldrich, E., Simpson, E., Rosmarin, D., Elmaraghy, H., Meskimen, E., Natalie, C. R., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad022 · Cited by 163 · cited 2×
“Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity and did not require treatment discontinuation [129,131,132].”
IL-31: A new key player in dermatology and beyond
Bağci, I. S., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.045 · Cited by 160
Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies
Bugaut, H., & Aractingi, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.621956 · Cited by 151 · cited 1×
“In response to stimulation by IL-23 and IL-1 β , activated Th17 lymphocytes produce several proinflammatory cytokines, including IL-17A, IL-17F, IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IFN-γ [31,65,66,70–73].”
Factors and Pathways Modulating Endothelial Cell Senescence in Vascular Aging
Hwang, H. J., Kim, N., Herman, A. B., Gorospe, M., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710135 · Cited by 149 · cited 6×
“Additionally, oxidative stress enhances endothelial cell senescence, thereby promoting vascular ageing and chronic inflammation [17].”
InfluentialHigh sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective
Pais, P., Kamath, D., Xavier, D., & Sigamani, A. (2015) · Indian Journal of Medical Research · doi:10.4103/0971-5916.166582 · Cited by 148 · cited 1×
“The ELISA method is also used to measure soluble P-selectin [55] and hsCRP. HsCRP can be measured in both fresh and frozen plasma and is one of the most frequently analysed biomarkers in the context of cardiovascular disease risk assessment [56].”
Yiu, Z. Z. N., Becher, G., Kirby, B., Laws, P., Reynolds, N. J., Smith, C. H., Warren, R. B., Griffiths, C. E. M., BADBIR Study Group, Browne, F., et al. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.2909 · Cited by 148 · cited 1×
“…or the p19 subunit of IL-23 have demonstrated superior efficacy, as evidenced by a higher proportion of patients achieving PASI 90 compared with earlier biologic therapies such as ustekinumab and tumour necrosis factor alpha (TNF-α ) inhibitors adalimumab, certolizumab, and etanercept [135,136].”
Role of IL-33-ST2 pathway in regulating inflammation: current evidence and future perspectives
Zhou, Y., Xu, Z., & Liu, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04782-4 · Cited by 148 · cited 1×
“ST2 co-stimulates T cell activation by enhancing clonal expansion and promoting the production of cytokines and chemokines [42,44].”
Su, Y., Huang, J., Zhao, X., Lu, H., Wang, W., Yang, X. O., Shi, Y., Wang, X., Lai, Y., & Dong, C. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau9657 · Cited by 146 · cited 1×
“IL-17 is a key mediator of sustained chronic inflammation, especially in immune-mediated diseases such as psoriasis (Figure 3) [32,69,74,75].”
Ascott, A., Mulick, A., Yu, A. M., Prieto-Merino, D., Schmidt, M., Abuabara, K., Smeeth, L., Roberts, A., & Langan, S. M. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.030 · Cited by 144
SIRT1 and SIRT6: The role in aging-related diseases
You, Y., & Liang, W. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166815 · Cited by 142 · cited 3×
“Numerous studies have demonstrated that the SIRT1– NF-κ B pathway plays a significant role in counteracting cellular senescence and exerting anti-inflammatory effects [23–25].”
Agrawal, R., Hu, A., & Bollag, W. B. (2023) · Biology · doi:10.3390/biology12111396 · Cited by 137 · cited 2×
“…and vascular damage, and is associated with elevated levels of inflammatory biomarkers, thereby facilitating the development of comorbidities [7,60,108] Studies have shown that chronic activation of the Th2 axis in adult patients with atopic dermatitis is associated with an increased risk of…”
Francis, L., McCluskey, D., Gânier, C., Jiang, T., Du-Harpur, X., Gabriel, J., Dhami, P., Kamra, Y., Visvanathan, S., Barker, J. N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44994-w · Cited by 136
The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
Egeberg, A., Gisondi, P., Carrascosa, J. M., Warren, R. B., & Mrowietz, U. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16273 · Cited by 133 · cited 2×
“Prolonged activation of the Th17-dependent inflammatory pathway promotes inflammageing and contributes to accelerated biological ageing [62–64].”
Schäkel, K., Reich, K., Asadullah, K., Pinter, A., Jullien, D., Weisenseel, P., Paul, C. F., Gomez, M., Wegner, S., Personke, Y., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19236 · Cited by 133 · cited 1×
“…psoriasis lesions during ustekinumab therapy who switched to guselkumab showed improvements in skin clearance and quality of life [166–168 Early initiation of guselkumab therapy after psoriasis diagnosis may contribute to achieving a better clinical response and a faster therapeutic effect [173].”
Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis
Hjuler, K. F., Bøttcher, M., Vestergaard, C., Deleuran, M. S., Raaby, L., Bøtker, H. E., Iversen, L., & Kragballe, K. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.041 · Cited by 130 · cited 1×
“The exact mechanisms underlying the relationship between chronic systemic inflammation and elevated cardiovascular risk are not yet fully understood and require further investigation [108–111].”
The IL‐13/periostin/IL‐24 pathway causes epidermal barrier dysfunction in allergic skin inflammation
Mitamura, Y., Nunomura, S., Nanri, Y., Ogawa, M., Yoshihara, T., Masuoka, M., Tsuji, G., Nakahara, T., Hashimoto‐Hachiya, A., Conway, S. J., et al. (2018) · Allergy · doi:10.1111/all.13437 · Cited by 130 · cited 1×
“These components are essential for preserving the integrity of the skin barrier [35,36,107].”
Ma, R., Cui, L., Cai, J., Yang, N., Wang, Y., Chen, Q., Chen, W., Peng, C., Qin, H., Ding, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1323174 · Cited by 130 · cited 1×
“Infliximab TNF-α Preventing interaction between TNF-α and its receptors [138,192] Adalimumab TNF-α Preventing interaction between TNF-α and its receptors [138,193] Etanercept TNF-α Receptor fusion protein inhibiting TNF-α signalling [138,194]”
Bagel, J., Duffin, K. C., Moore, A. Y., Ferris, L. K., Siu, K., Steadman, J., Kianifard, F., Nyirady, J., & Lebwohl, M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.033 · Cited by 129 · cited 1×
“Moreover, it demonstrates good efficacy in the treatment of extensive scalp psoriasis, improving patient outcomes and quality of life [140].”
SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., & Elekhnawy, E. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01125-5 · Cited by 126 · cited 3×
“SIRT1 negatively regulates p53 by deacetylating it, thereby limiting DNA damage and reducing cellular senescence [23,24].”
Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Olbrich, H., Sadik, C. D., Ludwig, R. J., Thaçi, D., & Boch, K. (2023) · Biomolecules · doi:10.3390/biom13040634 · Cited by 123 · cited 1×
“These mechanisms are fundamental to the pathogenesis of the disease, contributing to the maintenance of chronic inflammation and the exacerbation of symptoms [85,86].”
Blauvelt, A., Leonardi, C., Elewski, B., Crowley, J. J., Guenther, L. C., Gooderham, M., Langley, R. G., Vender, R., Pinter, A., Griffiths, C. E. M., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19509 · Cited by 122 · cited 1×
“Another key advantage is its faster onset of therapeutic effect compared to IL-23 inhibitors [147,150,151].”
Tamagawa‐Mineoka, R., Katoh, N., & Kishimoto, S. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.06.053 · Cited by 121 · cited 1×
“Clinical improvement was associated with a reduction in its levels, suggesting its potential use as a marker of treatment response [231].”
Inflammation and aging-related disease: A transdisciplinary inflammaging framework
Andonian, B. J., Hippensteel, J. A., Abuabara, K., Boyle, E. M., Colbert, J. F., Devinney, M. J., Faye, A. S., Kochar, B. D., Lee, J., Litke, R. R., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01364-0 · Cited by 121 · cited 1×
“Inflammageing reflects a disruption in immune system homeostasis, marked by an imbalance in pro-and anti-inflammatory signalling, and provides a framework linking immune dysregulation to age-associated decline in tissue function [1,2,4,5].”
Behzadi, P., Behzadi, E., & Ranjbar, R. (2016) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.63.2016.1.1 · Cited by 120 · cited 1×
“It belongs to the IL-12 cytokine family, along with IL-12, IL-27, and IL-35 [68].”
McInnes, I. B., Rahman, P., Gottlieb, A. B., Hsia, E. C., Kollmeier, A. P., Xu, X. L., Jiang, Y., Sheng, S., Shawi, M., Chakravarty, S. D., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.42010 · Cited by 118 · cited 1×
“Additionally, it demonstrates efficacy in the treatment of active psoriatic arthritis [167–171].”
Berdyshev, E., Goleva, E., Bissonnette, R., Bronova, I., Bronoff, A. S., Richers, B. N., Garcia, S., Ramirez‐Gama, M., Taylor, P., Praestgaard, A., et al. (2022) · Allergy · doi:10.1111/all.15432 · Cited by 116 · cited 1×
“It is used in patients with moderate to severe atopic dermatitis and has a favourable safety profile, confirmed by numerous clinical trials [38,115–122].”
Drucker, A. M., Lam, M., Prieto‐Merino, D., Malek, R., Ellis, A. G., Yiu, Z. Z. N., Rochwerg, B. N., Giorgio, S. D., Arents, B. W. M., Mohan, T., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.2192 · Cited by 115 · cited 2×
“It is a high-affinity monoclonal antibody that selectively binds to interleukin-13 [128,129].”
High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes
Denegri, A., & Boriani, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200717090334 · Cited by 113 · cited 1×
“Studies have shown an association between hsCRP levels and the presence of cardio-vascular diseases and atherosclerosis, which is why it is considered a potential indicator or predictor of disease occurrence [50,51].”
Atopic dermatitis and risk of ischemic stroke: A nationwide population-based study
Su, V. Y.-F., Chen, T.-J., Yeh, C.-M., Chou, K.-T., Hung, M.-H., Chu, S.-Y., Su, K.-C., Chang, Y.-S., Lin, Y.-H., & Liu, C.-J. (2014) · Annals of Medicine · doi:10.3109/07853890.2013.870018 · Cited by 103 · cited 1×
“Moreover, the risk of ischemic stroke increases with the severity of atopic dermatitis [214].”
Elyahu, Y., & Monsonego, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101231 · Cited by 103 · cited 3×
“Key systemic features of immunosenescence include thymic involution and hematopoietic stem cell (HSC) dysfunction [1,3,8,9].”
Bando, T., Morikawa, Y., Komori, T., & Senba, E. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.009 · Cited by 102
Thaci, D., Piaserico, S., Warren, R. B., Gupta, A. K., Cantrell, W., Draelos, Z., Foley, P., Igarashi, A., Langley, R. G., Asahina, A., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19866 · Cited by 102
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
Haddad, E., Cyr, S. L., Arima, K., McDonald, R. A., Levit, N. A., & Nestle, F. O. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00737-7 · Cited by 102 · cited 2×
“This disease is characterised by a predominant immune response driven by activation of the Th2 inflammatory axis, making blockade of the key cytokines in this pathway an effective therapeutic approach [7,112,113].”
Principles of the Molecular and Cellular Mechanisms of Aging
da Silva, P. F. L., & Schumacher, B. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.018 · Cited by 100 · cited 5×
“These changes reduce ATP production and increase reactive oxygen species (ROS) generation, contributing significantly to oxidative damage during ageing [15].”
InfluentialBrezinski, E. A., Follansbee, M. R., Armstrong, E. J., & Armstrong, A. W. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282004140213123852 · Cited by 98 · cited 1×
“Biological therapies, including TNF-α inhibitors, may exert a positive effect by improving endothelial cell function [228,247].”
Cho, J. J., Xu, Z., Parthasarathy, U., Drashansky, T. T., Helm, E. Y., Zuniga, A. N., Lorentsen, K. J., Mansouri, S., Cho, J. Y., Edelmann, M. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08605-3 · Cited by 98 · cited 2×
“Together, TGF-β and IL-6 also induce the expression of the primary Th17-specific transcription factor, retinoid-related orphan receptor-γ t (ROR-γ t) [65,66].”
Sirtuin 1 and Skin: Implications in Intrinsic and Extrinsic Aging—A Systematic Review
Bielach-Bazyluk, A., Zbroch, E., Myśliwiec, H., Rydzewska–Rosołowska, A., Kakareko, K., Flisiak, I., & Hryszko, T. (2021) · Cells · doi:10.3390/cells10040813 · Cited by 97 · cited 1×
“The diverse functions of sirtuin 1 suggest its beneficial role in delaying skin ageing [255].”
Medovic, M. V., Jakovljevic, V. L., Zivkovic, V. I., Jeremic, N. S., Jeremic, J. N., Bolevich, S., Ravić‐Nikolić, A., Milicic, V. M., & Srejovic, I. M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2249834 · Cited by 94 · cited 2×
“Biological drugs, such as IL-17A, IL-12/23, and TNF-α inhibitors, used in the treatment of chronic inflammatory dermatoses, exhibit potential antioxidant effects by reducing oxidative stress, limiting persistent inflammation driven by free radicals, and modulating the immune response [236,239–242].”
Reich, K., Griffiths, C. E. M., Gordon, K. B., Papp, K. A., Song, M., Randazzo, B., Li, S., Shen, Y.-K., Han, C., Kimball, A. B., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.11.040 · Cited by 93 · cited 1×
“…residual psoriasis lesions during ustekinumab therapy who switched to guselkumab showed improvements in skin clearance and quality of life [166–168 Early initiation of guselkumab therapy after psoriasis diagnosis may contribute to achieving a better clinical response and a faster therapeutic…”
Cellular Senescence: Mechanisms and Therapeutic Potential
Liao, Z., Yeo, H. L., Wong, S. W., & Zhao, Y. X. (2021) · Biomedicines · doi:10.3390/biomedicines9121769 · Cited by 92 · cited 2×
“The cellular senescence mechanism serves a protective role by helping to prevent the development of cancer through the inhibition of uncontrolled cell proliferation [14,20,21].”
Jókai, H., Szakonyi, J., Kontár, O., Marschalkó, M., Szalai, K., Kárpáti, S., & Holló, P. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.06.019 · Cited by 91 · cited 1×
“Patients with severe psoriasis have been shown to exhibit increased carotid IMT (cIMT) compared to healthy controls [243–245].”
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91
Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
Wang, F., Tang, X., Wei, C., Xu, L., Mao, H. Z., & Luo, F. (2018) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2018.01.016 · Cited by 89
Anti-Inflammatory Role of the Klotho Protein and Relevance to Aging
Prud’homme, G. J., & Wang, Q. (2024) · Cells · doi:10.3390/cells13171413 · Cited by 87 · cited 1×
“Both Klotho expression and circulating concentrations decline with age, and this reduction may serve as an early marker of premature vascular ageing and atherosclerosis [258–261].”
Fassett, M. S., Bráz, J. M., Castellanos, C. A., Salvatierra, J. J., Sadeghi, M., Yu, X., Schroeder, A., Caston, J., Muñoz-Sandoval, P., Roy, S., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abi6887 · Cited by 86 · cited 1×
“One example of this approach is nemolizumab, a humanised monoclonal antibody targeting the IL-31RA receptor, which has demonstrated efficacy in alleviating itch [102–104].”
Barygina, V. V., Becatti, M., Soldi, G., Prignano, F., Lotti, T., Nassi, P., Wright, D., Taddei, N., & Fiorillo, C. (2013) · Redox Report · doi:10.1179/1351000213y.0000000045 · Cited by 85 · cited 1×
“Biological drugs, such as IL-17A, IL-12/23, and TNF-α inhibitors, used in the treatment of chronic inflammatory dermatoses, exhibit potential antioxidant effects by reducing oxidative stress, limiting persistent inflammation driven by free radicals, and modulating the immune response [236,239–242].”
Th17/IL-17 induces endothelial cell senescence via activation of NF-κB/p53/Rb signaling pathway
Zhang, L., Liu, M., Liu, W., Hu, C., Li, H., Deng, J., Cao, Q., Wang, Y., Hu, W., & Li, Q. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00629-y · Cited by 85 · cited 2×
“In a study conducted by Liang Zhang et al., inhibition of the NF-κ B pathway using ammonium pyrrolidinedithiocarbamate (PDTC) effectively suppressed IL-17A-induced expression of senescence-associated proteins [34].”
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Thomas, S. E., Barenbrug, L., Hannink, G., Seyger, M. M. B., de Jong, E. M. G. J., & van den Reek, J. M. P. A. (2024) · Drugs · doi:10.1007/s40265-024-02028-1 · Cited by 83 · cited 2×
“The latest biologic drugs approved for the treatment of moderate to severe psoriasis include inhibitors of interleukin (IL)-17 and IL-23 [133].”
Targeting Skin Barrier Function in Atopic Dermatitis
van den Bogaard, E. H., Elias, P. M., Goleva, E., Berdyshev, E., Smits, J. P. H., Danby, S. G., Cork, M. J., & Leung, D. Y. M. (2023) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2023.02.005 · Cited by 81 · cited 2×
“Mechanisms leading to skin barrier dysfunction in chronic inflammatory skin diseases, including atopic dermatitis, may serve as a foundation for developing new and innovative therapeutic strategies [107].”
Ranking Biomarkers of Aging by Citation Profiling and Effort Scoring
Hartmann, A., Hartmann, C., Secci, R., Hermann, A., Fuellen, G., & Walter, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.686320 · Cited by 80
Gold, L. S., Thaçi, D., Thyssen, J. P., Gooderham, M., Laquer, V. T., Moore, A. Y., Natalie, C. R., Zhao, F., Meskimen, E., Elmaraghy, H., et al. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00792-6 · Cited by 80 · cited 2×
“Most treatment-emergent adverse events (TEAEs) were mild or moderate in severity and did not require treatment discontinuation [129,131,132].”
Klotho antiaging protein: molecular mechanisms and therapeutic potential in diseases
Hajare, A. D., Dagar, N., & Gaikwad, A. B. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00253-y · Cited by 80
Garbaravičienė, J., Diehl, S., Varwig, D., Bylaitė, M., Ackermann, H., Ludwig, R. J., & Boehncke, W. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2010.01095.x · Cited by 79 · cited 1×
“Therefore, P-selectin levels may potentially serve as a biomarker for assessing treatment efficacy in these conditions [230,232].”
The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities
Yost, J. M., & Gudjonsson, J. E. (2009) · F1000 Medicine Reports · doi:10.3410/m1-30 · Cited by 78 · cited 4×
“Among TNF-α inhibitors, infliximab is the most effective drug for treating psoriasis, followed by adalimumab, while etanercept exhibits the weakest therapeutic effect in this indication [187,190].”
InfluentialOxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment
Bacchetti, T., Campanati, A., Ferretti, G., Simonetti, O., Liberati, G., & Offidani, A. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12144 · Cited by 77 · cited 1×
“For example, in a clinical study conducted by Bacchetti et al., treatment with etanercept was associated with reduced lipid peroxidation and improved antioxidant parameters, correlating with clinical improvement [240].”
Blauvelt, A., Lebwohl, M., Mabuchi, T., Leung, A., Garrelts, A., Crane, H. M., Elmaraghy, H., Patel, H., Ridenour, T., See, K., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.11.022 · Cited by 76 · cited 1×
“Its efficacy and safety in treating patients with moderate to severe plaque psoriasis or active psoriatic arthritis, particularly those who have had inadequate response to prior tumour necrosis factor inhibitor therapy, have been confirmed in clinical trials [135,144–149].”
Giuliani, A., Prattichizzo, F., Micolucci, L., Ceriello, A., Procopio, A. D., & Rippo, M. R. (2017) · Mediators of Inflammation · doi:10.1155/2017/2309034 · Cited by 73 · cited 1×
“…contribute to disease pathogenesis through three mechanisms: (i) oxidative stress and disrupted lipid metabolism, (ii) mitochondrial alterations in keratinocytes following pharmacological treatment, and (iii) elevated serum levels of mitochondrial DNA (mtDNA), which trigger inflammation [249–251].”
Visvanathan, S., Baum, P., Vinisko, R., Schmid, R., Flack, M., Lalovic, B. B., Kleiner, O., Fuentes‐Duculan, J., Garcet, S., Davis, J. W., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.042 · Cited by 73 · cited 1×
“Furthermore, it more strongly modulated gene expression, significantly reducing the expression of genes related to keratinocytes, epidermal cells, and monocytes, which may explain its superior control of skin inflammation [262].”
Biomarkers of the ageing immune system and their association with frailty – A systematic review
Tran Van Hoi, E., De Glas, N. A., Portielje, J. E. A., Van Heemst, D., Van Den Bos, F., Jochems, S. P., & Mooijaart, S. P. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112163 · Cited by 69 · cited 2×
“Commonly analysed biomarkers potentially associated with ageing include IL-6, hs-CRP, VCAM-1, ICAM-1, and IL-17A [79,218–220] Additionally, evidence indicates a significant role for soluble selectins, such as sP-selectin, in endothelial dysfunction and the development of atherosclerosis, which may…”
Yasmeen, N., Sawyer, L., Malottki, K., Levin, L., Apol, E. D., & Jemec, G. B. E. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1743811 · Cited by 68 · cited 1×
“Its high efficacy in the treatment of moderate to severe psoriasis has been confirmed in clinical trials [135,165,174–176].”
Interleukin-31 pathway and its role in atopic dermatitis: a systematic review
Saleem, M. D., Oussedik, E., D’Amber, V., & Feldman, S. R. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1290205 · Cited by 67 · cited 1×
“One example of this approach is nemolizumab, a humanised monoclonal antibody targeting the IL-31RA receptor, which has demonstrated efficacy in alleviating itch [102–104].”
Strober, B., Menter, A., Leonardi, C., Gordon, K., Lambert, J., Puig, L., Photowala, H., Longcore, M., Zhan, T., & Foley, P. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16521 · Cited by 67 · cited 2×
“Currently, however, biological drugs that specifically block the p19 subunit of IL-23, such as guselkumab, risankizumab and tildrakizumab, enable a more precise therapeutic approach thanks to their selective mechanism of action [6,165–167].”
Endothelial Dysfunction in Psoriasis: An Updated Review
Anyfanti, P., Margouta, A., Goulas, K., Gavriilaki, M., Lazaridou, E., Patsatsi, A., & Gkaliagkousi, Ε. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.864185 · Cited by 67 · cited 1×
“Additionally, they may function as diagnostic markers for assessing cardiovascular risk in patients with chronic inflammatory diseases [43,226,227] With age and biological ageing, serum levels of VCAM-1 and ICAM-1 increase, a change associated with the process of inflammageing [220].”
The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis
Pappa, G., Sgouros, D., Theodoropoulos, K., Κανελλέας, Α., Bozi, E., Gregoriou, S., Krasagakis, K., & Katoulis, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195633 · Cited by 67 · cited 5×
“These cytokines induce the production of eotaxins, which promote the recruitment of additional Th2 cells and perpetuate chronic inflammation in atopic diseases [82].”
InfluentialSkin immunity and its dysregulation in psoriasis
Lanna, C., Mancini, M., Gaziano, R., Cannizzaro, M. V., Galluzzo, M., Talamonti, M., Rovella, V., Annicchiarico‐Petruzzelli, M., Melino, G., Wang, Y., et al. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1653099 · Cited by 65 · cited 2×
“IL-17 is a key mediator of sustained chronic inflammation, especially in immune-mediated diseases such as psoriasis (Figure 3) [32,69,74,75].”
Emerging Biologic Therapies for the Treatment of Atopic Dermatitis
Alvarenga, J. M., Bieber, T. R. M., & Torres, T. R. (2024) · Drugs · doi:10.1007/s40265-024-02095-4 · Cited by 64 · cited 3×
“Loss-of-function mutations in the FLG gene, which encodes filaggrin, are among the main risk factors for developing atopic dermatitis [89,106].”
Tsiogka, A., Gregoriou, S., Stratigos, A., Σουλαϊδόπουλος, Σ., Rompoti, N., Panagakis, P., Papoutsaki, M., Kostakis, P. G., Kontochristopoulos, G., Tsioufis, K. P., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020318 · Cited by 61 · cited 2×
“This approach could lead to improved overall health and quality of life for patients, as well as reduce the risk of developing comorbidities and slow down biological ageing processes [187,201–204].”
Signs of innate immune activation and premature immunosenescence in psoriasis patients
Šahmatova, L., Sügis, E., Šunina, M., Hermann, H., Prans, E., Pihlap, M., Abram, K., Rebane, A., Peterson, H., Peterson, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07975-2 · Cited by 59 · cited 1×
“However, further research is necessary to develop therapeutic approaches that can modulate these processes [210,215].”
SIRT1 Regulates CD40 Expression Induced by TNF-a via NF-?B Pathway in Endothelial Cells
Yang, L., Zhang, J., Yan, C., Zhou, J., Lin, R., Lin, Q., Wang, W., Zhang, K., Yang, G., Bian, X., et al. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000343318 · Cited by 58 · cited 1×
“In the future, SIRT1 activators may represent a novel, targeted therapeutic strategy for chronic inflammatory skin diseases, potentially preventing skin ageing and slowing vascular ageing [252,256,257].”
Varona, J. F., Ortiz-Regalón, R., Sánchez‐Vera, I., López‐Melgar, B., de Durango, C. G., Castellano, J. M., Solís, J., Fernández‐Friera, L., & Vidal‐Vanaclocha, F. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.05.003 · Cited by 58 · cited 1×
“Additionally, they may function as diagnostic markers for assessing cardiovascular risk in patients with chronic inflammatory diseases [43,226,227] With age and biological ageing, serum levels of VCAM-1 and ICAM-1 increase, a change associated with the process of inflammageing [220].”
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
Orfali, R. L., & Aoki, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020577 · Cited by 58 · cited 2×
“It belongs to the IL-6 cytokine family, and its receptor is a heterodimeric complex composed of the IL-31RA subunit and the oncostatin M receptor (OSMR) [83,91–93].”
Santos-Moreno, P., Burgos-Angulo, G., Martínez‐Ceballos, M. A., Pizano, A., Echeverri, D., Bautista‐Niño, P. K., Roks, A. J. M., & Rojas‐Villarraga, A. (2021) · RMD Open · doi:10.1136/rmdopen-2020-001470 · Cited by 55 · cited 1×
“This promotes vascular ageing and damage, as evidenced by accelerated vascular wall remodelling and enhanced atherogenesis, a key risk factor for the development of cardiovascular diseases [217].”
Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis
Koskeridis, F., Εvangelou, Ε., Ntzani, E., Κostikas, Κ., & Tsabouri, S. (2022) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754221130969 · Cited by 55 · cited 1×
“Blocking the signalling of IL-4 and IL-13 [117] Tralokinumab IL-13 Preventing receptor interaction and downstream signalling [127] Lebrikizumab IL-13 Preventing the formation of the IL-4R α /IL-13R α 1 heterodimer receptor signalling complex [131–133] Inhibitors of IL-17”
Papp, K. A., Blauvelt, A., Puig, L., Ohtsuki, M., Beissert, S., Gooderham, M., Amin, A. Z., Liu, J., Wu, T., Azam, T., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.07.1024 · Cited by 55
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
Savage, L. J., Wittmann, M., McGonagle, D., & Helliwell, P. S. (2015) · Rheumatology and Therapy · doi:10.1007/s40744-015-0010-2 · Cited by 53
IL-31: State of the Art for an Inflammation-Oriented Interleukin
Borgia, F., Custurone, P., Pomi, F. L., Cordiano, R., Alessandrello, C., & Gangemi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126507 · Cited by 52 · cited 2×
“IL-31 is primarily produced by Th2 lymphocytes, but also by monocytes, macrophages, dendritic cells, fibroblasts, and keratinocytes [96].”
Fan, X., Yan, K., Meng, Q., Sun, R., Yang, X., Yuan, D., Li, F., & Deng, H. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4173 · Cited by 50 · cited 1×
“SIRT1 modulates inflammation-related signalling pathways and suppresses the production of reactive oxygen species (ROS) in mitochondria, thereby reducing oxidative stress, mitochondrial DNA mutations, and mitochondrial damage [252–254].”
Villani, A. P., Pavel, A. B., Wu, J., Fernandes, M., Maari, C., Proulx, É. S., Jack, C. S., Glickman, J. W., Choi, S., He, H., et al. (2021) · Allergy · doi:10.1111/all.14859 · Cited by 50 · cited 1×
“Infliximab TNF-α Preventing interaction between TNF-α and its receptors [138,192] Adalimumab TNF-α Preventing interaction between TNF-α and its receptors [138,193] Etanercept TNF-α Receptor fusion protein inhibiting TNF-α signalling [138,194]”
Kimball, A. B., Luger, T. A., Gottlieb, A. B., Puig, L., Kaufmann, R., Nikaï, E., Zhu, B., Edson‐Heredia, E., Carlier, H., Lin, C.-Y., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.034 · Cited by 48 · cited 1×
“Another key advantage is its faster onset of therapeutic effect compared to IL-23 inhibitors [147,150,151].”
Martínez‐López, A., Blasco‐Morente, G., Pérez‐López, I., Tercedor‐Sánchez, J., & Arias‐Santiago, S. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14841 · Cited by 48 · cited 1×
“This suggests a beneficial effect of reducing chronic systemic inflammation on vascular health and its related outcomes [246].”
Iversen, L., Conrad, C., Eidsmo, L., Costanzo, A., Narbutt, J., Pinter, A., Kingo, K., Diaz, R. R., Kolbinger, F., Nanna, M., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18846 · Cited by 47 · cited 1×
“Initiating therapy at an early stage of the disease may result in greater treatment benefits [142].”
Strober, B. E., Paul, C. F., Blauvelt, A., Thaçi, D., Puig, L., Lebwohl, M., White, K., Vanvoorden, V., Deherder, D., Gómez, N. N., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.04.063 · Cited by 47 · cited 1×
“Simultaneous blockade of both cytokines, which are key mediators of the Th17-dependent inflammatory axis, may lead to more effective suppression of inflammation than neutralising IL-17A alone in patients with moderate to severe psoriasis [152–154].”
Strober, B. E., Sigurgeirsson, B., Popp, G., Sinclair, R. D., Krell, J. M., Stonkus, S., Septe, M., Elewski, B. E., Gottlieb, A. B., Zhao, Y., et al. (2016) · International Journal of Dermatology · doi:10.1111/ijd.13236 · Cited by 46 · cited 1×
“Infliximab TNF-α Preventing interaction between TNF-α and its receptors [138,192] Adalimumab TNF-α Preventing interaction between TNF-α and its receptors [138,193] Etanercept TNF-α Receptor fusion protein inhibiting TNF-α signalling [138,194]”
Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis
Muramatsu, S., Kubo, R., Nishida, E., & Morita, A. (2016) · Modern Rheumatology · doi:10.3109/14397595.2016.1174328 · Cited by 46 · cited 1×
“Serum IL-6 levels can be used as indicators of disease activity and severity, and a decrease following biological therapy enables the assessment of treatment response in patients with psoriasis [218,221,222].”
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero, A., Potestio, L., Camela, E., Fabbrocini, G., & Megna, M. (2022) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s367744 · Cited by 44 · cited 1×
“However, bimekizumab was associated with a higher incidence of oral candidiasis, which was typically mild to moderate in severity [153–155].”
Tamagawa‐Mineoka, R., Katoh, N., Ueda, E., Masuda, K., & Kishimoto, S. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.006 · Cited by 43 · cited 1×
“In addition to their roles in hemostasis and thrombosis, platelets amplify inflammation and act as important modulators of the immune response [230–233].”
Visser, M. J. E., Venter, C., Roberts, T. J., Tarr, G. S., & Pretorius, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-90684-8 · Cited by 42
Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis
Simopoulou, T., Tsiogkas, S. G., Zafiriou, E., & Bogdanos, D. P. (2023) · Drugs of today · doi:10.1358/dot.2023.59.3.3419557 · Cited by 39 · cited 1×
“Interleukin-17 inhibitors include secukinumab, ixekizumab, and bimekizumab [6,134,135].”
Pro‐inflammatory cytokines mediating senescence of vascular endothelial cells in atherosclerosis
Shang, D., Liu, H., & Tu, Z. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12915 · Cited by 39 · cited 3×
“These processes accelerate the development and progression of atherosclerosis (AS) [80,81].”
Cited by
Skin aging: Mechanistic insights and targeted therapeutic strategies
Beaziz, J., Avallone, G., Langer, K., DUCA, E. D., Navrazhina, K., He, H., & Guttman‐Yassky, E. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.05.015 · Cited by 3
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1
Wang, K., & Zhang, J. (2026) · Journal of Science Advanced Materials and Devices · doi:10.1016/j.jsamd.2026.101177 · Cited by 1
Glucagon-like peptide-1 receptor agonists as metabolic adjuncts in immune-mediated skin disease
Lazarowitz, R., Saroufim, L., Sauder, M. B., Osman, M. S., Tardio, V., Litvinov, I. V., & Netchiporouk, E. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.02.047
Kim, T.-H., Shin, S., & Park, W. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00809-2
“Importantly, as the disease becomes chronic, the structural deformation of tissues becomes accompanied by inflammation (Andrzejczak et al. 2025).”
Metadata
- Authors
- Andrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M.
- Affiliations
- Wroclaw Medical University (PL)
- Corresponding author
- Ponikowska, Małgorzata
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2025-09-15
- Volume
- 14
- Issue
- 18
- Pages
- 1442
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC12469205
- OpenAlex
- W4414206127
- Semantic Scholar
- 77db497849c105e7ce9941bcc0c7f75dfe8f5147
- Cited by
- 10
- References
- 265
- Citations by year
- 2026: 10
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wroclaw Medical University
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Skin Protection and Aging
- Keywords
- inflammaging, chronic inflammatory skin disease, atopic dermatitis, psoriasis, hidradenitis suppurativa, Th17 cells, Th2 cells, IL-17, IL-23, IL-4, IL-13, IL-31, oxidative stress, endothelial dysfunction, Klotho, SIRT1, vascular biomarkers, VCAM-1, ICAM-1, ST2, P-selectin, biologic therapy, systemic inflammation
- MeSH terms
- Aging, Animals, Biological Therapy, Chronic Disease, Humans, Inflammation, Skin Diseases, Cytokines, Cellular Senescence, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


